Quality of life
Quality of life Disease control
A dark and shadowy image of a couch. A dark and shadowy image of a couch.

Patients want HAE control without trade-offs

Quality of life

In the 6-month placebo-controlled study

Patients reported improved QoL with DAWNZERA

DAWNZERA every 4 weeks significantly improved Angioedema Quality of Life (AE-QoL) scores—a validated measure in patients with angioedema1-3

Improvements from baseline in LSM AE-QoL score with DAWNZERA at Week 241

A bar chart showing DAWNZERA every 4 weeks significantly improved scores on the Angioedema Quality of Life measure. A bar chart showing DAWNZERA every 4 weeks significantly improved scores on the Angioedema Quality of Life measure.
NR=not reported.

DAWNZERA

improved patient AE-QoL scores MORE THAN 3X beyond the minimum clinically important difference (>6 points)1

Disease control
>90% of patients reported they were well-controlled with DAWNZERA
Disease control was self-reported by patients on the Angioedema Control Test (AECT)2
Text reading 'Well-Controlled'
Mean proportion of patients well-controlled on DAWNZERA (AECT)1,4
A bar chart showing over 90% of patients in clinical studies reported they were well-controlled with DAWNZERA. A bar chart showing over 90% of patients in clinical studies reported they were well-controlled with DAWNZERA.
Neon lettering reading ">90".
of patients
achieved well-controlled disease1,4

Well-controlled was defined as ≥10 out of 16 possible points on the AECT5*

Scores of 0 to 9 equated to poorly-controlled angioedema
*The AECT was validated in 81 patients with recurrent angioedema, including 25 with HAE or acquired angioedema due to C1-INH deficiency. It was not specifically validated for HAE.5

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.